Silence Therapeutics (SLN) Net Income towards Common Stockholders: 2020-2025
Historic Net Income towards Common Stockholders for Silence Therapeutics (SLN) over the last 6 years, with Sep 2025 value amounting to -$21.0 million.
- Silence Therapeutics' Net Income towards Common Stockholders rose 41.04% to -$21.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$64.5 million, marking a year-over-year increase of 24.27%. This contributed to the annual value of -$45.3 million for FY2024, which is 16.45% up from last year.
- Per Silence Therapeutics' latest filing, its Net Income towards Common Stockholders stood at -$21.0 million for Q3 2025, which was up 23.38% from -$27.4 million recorded in Q2 2025.
- Silence Therapeutics' Net Income towards Common Stockholders' 5-year high stood at $12.3 million during Q4 2024, with a 5-year trough of -$35.5 million in Q3 2024.
- Moreover, its 3-year median value for Net Income towards Common Stockholders was -$18.6 million (2023), whereas its average is -$16.8 million.
- Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first skyrocketed by 166.23% in 2024, then tumbled by 1,134.00% in 2025.
- MRQ analysis of 5 years shows Silence Therapeutics' Net Income towards Common Stockholders stood at -$15.1 million in 2021, then decreased by 16.64% to -$17.7 million in 2022, then fell by 5.23% to -$18.6 million in 2023, then soared by 166.23% to $12.3 million in 2024, then plummeted by 270.36% to -$21.0 million in 2025.
- Its last three reported values are -$21.0 million in Q3 2025, -$27.4 million for Q2 2025, and -$28.5 million during Q1 2025.